Study Identifies New Approach for Developing Simple-to-Use, ‘Shelf-Available’ COVID Treatment Options
Uniformed Services University of the Health Sciences (USU) via Newswise – An array of new, simple “shelf-available” SARS-CoV-2 treatment options could soon be available in the…
Monoclonal Antibody Treatment Taken by Hospitalized COVID-19 Patients Reduces Mortality
Duke Health via New-Medical – A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a…
Researchers Discover New, Potent COVID-19 Antibody Cocktail
Texas Biomedical Research Institute via Newswise – SAN ANTONIO (March 18, 2022) – As SARS-CoV-2 has continued to evolve and outsmart existing treatments, scientists have not let…
How Diet, Supplements and Lifestyle Changes Can Help Battle COVID
Dr. Tomislav Meštrović, MD, Ph.D. via News-Medical – A recent editorial in the journal Nutrients emphasizes how efficacious non-pharmacological interventions in conjunction with the promotion of…
UK Gives OK to Merck’s Breakthrough Anti-COVID Pill, Pfizer Announces Its Antiviral Pill Works Too
CBN News – The United Kingdom granted conditional authorization Thursday to the first pill officially shown to successfully treat COVID-19. It’s the first country to OK the treatment…
NIH Researchers Identify Potential New Antiviral Drug for COVID-19
NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development via EurekAlert – The experimental drug TEMPOL may be a promising oral antiviral treatment for…
FDA Approves First COVID-19 Drug: Antiviral Remdesivir
Associated Press via CBN News – US regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an…
CBD May Help Reduce Cytokine Storm and Excessive Lung Inflammation in COVID-19
Medical College of Georgia at Augusta University via News-Medical Net – Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is…